Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK invests $20mm in XenoPort stock, with option to buy $20mm more

Executive Summary

On the heels of terminating their five-year-old agreement for the restless legs syndrome product Horizant (gabapentin), GlaxoSmithKline PLC and XenoPort Inc. (neurological, musculoskeletal, and dermatological therapeutics) have decided to not completely sever ties. GSK has agreed to buy $20mm in XenoPort stock for approximately a 4.3% stake.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity

Related Companies